Difference between revisions of "How I Treat"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 122: Line 122:
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2019:''' Lavin & O'Donnell. [https://doi.org/10.1182/blood-2018-10-844936 How I treat low von Willebrand factor levels]
 
*'''2019:''' Lavin & O'Donnell. [https://doi.org/10.1182/blood-2018-10-844936 How I treat low von Willebrand factor levels]
 +
 +
==Cytopenias==
 +
 +
===[[Autoimmune cytopenia]]===
 +
*'''2022:''' Porpaczy & Jäger. [https://doi.org/10.1182/blood.2019003686 How I manage autoimmune cytopenias in patients with lymphoid cancer] [https://pubmed.ncbi.nlm.nih.gov/34517415/ PubMed]
 +
 +
===[[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]]===
 +
*'''2021:''' Ghanima et al. [https://doi.org/10.1182/blood.2021010968 How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment]
  
 
=Special considerations=
 
=Special considerations=

Revision as of 16:38, 7 September 2023

The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.

In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.

Note: this page is currently under construction.

Malignant hematology

Myeloid neoplasms

Acute lymphoblastic leukemia (ALL)

Acute myeloid leukemia (AML)

Chronic myeloid leukemia (CML)

Myelodysplastic syndrome (MDS)

Polycythemia vera (PV)

Lymphoid neoplasms

Adult T-cell leukemia-lymphoma (ATLL)

Castleman disease

Chronic lymphocytic leukemia (CLL/SLL)

Cutaneous T-cell lymphoma (CTCL)

Hodgkin lymphoma

Diffuse large B-cell lymphoma (DLBCL)

Follicular lymphoma (FL)

Large granular lymphocytic leukemia (T-LGL)

NK- and T-cell lymphoma

Prolymphocytic leukemia (T-PLL)

Waldenström macroglobulinemia (WM)

Plasma cell dyscrasias

Light-chain (AL) amyloidosis

Multiple myeloma

Histiocytic disorders

Hemophagocytic lymphohistiocytosis (HLH)

Classical hematology

Hemostasis and thrombosis

Acquired thrombotic thrombocytopenic purpura (aTTP)

Antiphospholipid antibody syndrome (APS)

Hemophilia

Thrombotic microangiopathy (TMA)

Venous thromboembolism (VTE)

von Willebrand disease (vWD)

Cytopenias

Autoimmune cytopenia

Immune thrombocytopenia (ITP)

Special considerations

Complications of treatment

Pediatrics

Children

Adolescents and young adults (AYA)

Pregnancy